Portage Biotech Rebrands to AlphaTON After $38M Fundraise, Stock Soars 30%

## Introduction  
Portage Biotech Inc (NASDAQ: PRTG) is a clinical-stage immuno-oncology company focused on developing therapies that target checkpoint resistance pathways. The company employs a model integrating expertise from drug discovery veterans, scientific oversight, and capital management to advance immunotherapy assets from preclinical stages through human proof-of-concept. Its portfolio includes five drug platforms with ten products in various stages of preclinical or clinical development.

## Corporate Structure  
Headquartered in Westport, Connecticut, Portage Biotech has a workforce of between 11 and 50 employees, including scientists, clinicians, and professionals with pharmaceutical experience. The leadership team has been involved in five oncology drug approvals, aligning with the company’s strategy to mitigate risks associated with early-stage development through a methodical selection process for its assets.



<img src="https://newschat-banner-g4g7dfhkbycuh5e4.z02.azurefd.net/attn/article_images/article_image_20250903_164746.jpg" alt="Immuno-oncology" style="width:100%;">
<p style="text-align: center; font-style: italic; color: #666; font-size: 0.9em; margin-top: 8px;">Immuno-oncology by National Cancer Institute</p>

## Recent Developments and News  
On September 3, 2025, Portage Biotech filed a Form 6-K announcing a name change to AlphaTON Capital Corp, with a planned ticker change from PRTG to ATON effective September 4, 2025. The filing reported an aggregate fundraising amounting to approximately $38.2 million, including a $35 million loan. Of the net proceeds, $4 million is designated for ongoing operations in the immune-oncology sector, while approximately 99% will be directed towards acquiring The Open Network (TON) tokens.  
Earlier filings include:  
- A Form S-8 on August 1, 2025, to register 197,743 ordinary shares under its Equity Incentive Plan for employee benefit purposes.  
- A Form 424B3 on July 28, 2025, reporting an increase in ordinary shares outstanding from 1,653,622 on March 31, 2025, to 2,278,622 on July 21, 2025, along with a closing share price of $5.74 on July 25, 2025.  

On September 3, 2025, the stock price was reported to have increased by 30.32% to close at $9.07 on NASDAQ, with a trading volume of 117,305 shares.

## Financial and Strategic Analysis  
The $38.2 million fundraising indicates a strategic move towards digital assets. While $4 million will support the ongoing immune-oncology R&D efforts, most of the proceeds are planned for investment in TON tokens, with intended strategies for staking and yield optimization. Future capital needs for the biotech pipeline may be addressed through private investments in public equity (PIPE), at-the-market offerings, and public offerings. Key risk factors include challenges in financing the immune-oncology business, regulatory considerations regarding digital assets, and market liquidity for TON tokens.  

The change in shares outstanding and the historical share price movement—from $5.74 on July 25, 2025, to $9.07 on September 3, 2025—suggest heightened market activity related to the company's strategic transition. Employee equity offerings, registered under Form S-8, are in place to encourage workforce retention and loyalty.

## Market Position and Industry Context  
Portage Biotech operates within the immuno-oncology sector, focusing on checkpoint inhibitors and combination therapies that aim to enhance treatment responses. Its six technology platforms have developed 14 candidates, particularly the adenosine inhibitor series (PORT-6 through PORT-9), aimed at targeting pathways in the tumor microenvironment. The company’s focus on advancing immunotherapy assets while exploring digital assets represents a strategy that may diversify its financial and operational dynamics within the biotechnology landscape.

## tl;dr  
On September 3, 2025, Portage Biotech filed a Form 6-K reporting a $38.2 million fundraising—including $35 million in loan proceeds—and announced its name change to AlphaTON Capital Corp, with a new ticker symbol ATON effective September 4, 2025. The stock rose 30.32% to $9.07, with plans to allocate approximately 99% of proceeds to TON tokens and $4 million to support ongoing immuno-oncology operations. The future outlook focuses on digital asset strategies, forthcoming equity offerings, and progress in its immunotherapy pipeline.